Clinical Trial

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

Study acronym: SERRA-I US
Recruiting
View on ClinicalTrials.gov →
Summary
VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-16
Trial Details
NCT Number NCT07449325
Lead Sponsor VahatiCor, Inc.
Conditions Angina Pectoris, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Vascular Diseases, Microvascular Angina
Enrollment 30 participants
Start Date 2026-04-07
Primary Completion 2026-11 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-15